New study explores best way to dose HIV prevention pills for transgender women on hormones
NCT ID NCT04760691
First seen Apr 07, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study involved 13 transgender women to see how Truvada® (a daily pill to prevent HIV) interacts with feminizing hormones like estrogen. Participants took Truvada® alone and then with added hormones, and researchers measured drug levels in blood and tissues. The goal was to find the right dosing to keep the HIV prevention effective while on hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins School of Medicine Drug Development Unit
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.